Fig. 1 | Leukemia

Fig. 1

From: How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey

Fig. 1

Start of cytoreductive therapies in ET and PV patients (a) and start of ruxolitinib in MF and PV patients during the COVID-19 pandemic (b). HU hydroxyurea, IFN interferon, ET essential thrombocythemia, PV polycythemia vera, MF myelofibrosis. Survey data were collected and managed using the REDCap electronic data capture tools hosted at the GIMEMA Foundation. Most responders have >10 years of clinical experience on MPNs and >20 patients in annual follow-up for each disease. However, only 10.9% of the clinicians directly followed MPN patients affected by COVID-19.

Back to article page